FX-06

• UNSPSC Description:

  FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS)[1][2][4].

• Target Antigen:

  Dengue virus; Flavivirus

• Type:

  Peptides

• Related Pathways:

  Anti-infection

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/fx-06.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C(=O)(N1[C@H](C(=O)N2[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(NCC(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CCCNC(=N)N)C(O)=O)=O)=O)=O)=O)=O)CO)=O)[C@H](CC)C)=O)CCC2)CCC1)[C@H]4N(C([C@@H](NC(=O)[C@H]5N(C([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@H]6N(C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@H]7N(C([C@@H](NC([C@H](CC8=CN=CN8)NC(CN)=O)=O)CCCNC(=N)N)=O)CCC7)CC(C)C)=O)CC(O)=O)=O)CCCCN)=O)CCCCN)=O)CCCNC(=N)N)=O)CCC(O)=O)=O)CCC(O)=O)=O)C)=O)CCC6)CO)=O)CC(C)C)=O)CCCNC(=N)N)=O)CCC5)C)=O)CCC4

• Molecular Weight:

  3039.41

• References & Citations:

  [1]Ahrens I, et al. FX-06, a fibrin-derived Bbeta15-42 peptide for the potential treatment of reperfusion injury following myocardial infarction. Curr Opin Investig Drugs. 2009 Sep;10(9):997-1003. |[2]Zou F, et al. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. Bioorg Med Chem Lett. 2018 Feb 1;28(3):388-393. |[3]Roesner JP, et al. Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit Care Med. 2009 Feb;37(2):598-605. |[4]Gröger M, et al. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS One. 2009;4(4):e5391. |[5]Aparna Krishnamoorthy, et al. Fibrinogen β–derived Bβ15-42 peptide protects against kidney ischemia/ reperfusion injury. Blood (2011) 118 (7): 1934–1942.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  88650-17-3